Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LONQUEX versus Neulasta versus placebo in first-line advanced NSCLC
2014-005096-85Phase 4Completed
- Sponsor
- Merckle GmbH
- Start
- Mar 2015
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in non-small cell lung cancer (NSCLC) comparing LONQUEX plus first-line chemotherapy, Neulasta plus first-line chemotherapy and Placebo plus first-line chemotherapy (3 arms). Primary endpoint: Progression-free survival. Started Mar 2015; status: completed.
02
Drugs
lipegfilgrastimpegfilgrastim
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-005096-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005096-85.